Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PTCT Stock Forecast 2026-2027
$73.69
Current Price
$6.11B
Market Cap
Buy 9
Hold 5
Sell 1
Wall St Analyst Ratings
Distance to PTCT Price Targets
+68.3%
To High Target of $124.00
+16.7%
To Median Target of $86.00
-17.2%
To Low Target of $61.00
PTCT Price Momentum
+13.1%
1 Week Change
+4.0%
1 Month Change
+66.6%
1 Year Change
-3.0%
Year-to-Date Change
-15.8%
From 52W High of $87.50
+86.4%
From 52W Low of $39.53
📊 TOP ANALYST CALLS
Did PTCT Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if PTC Therapeutics is one of their latest high-conviction picks.
Latest PTCT Stock Price Targets & Analyst Predictions
Based on our analysis of 30 Wall Street analysts, PTCT has a bullish consensus with a median price target of $86.00 (ranging from $61.00 to $124.00). The overall analyst rating is Buy (7.6/10). Currently trading at $73.69, the median forecast implies a 16.7% upside. This outlook is supported by 9 Buy, 5 Hold, and 1 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PTCT Analyst Ratings
9
Buy
5
Hold
1
Sell
PTCT Price Target Range
Low
$61.00
Average
$86.00
High
$124.00
Current: $73.69
Latest PTCT Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PTCT.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Mar 30, 2026 | Jefferies | Faisal Khurshid | Hold | Downgrade | $76.00 |
| Feb 23, 2026 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $92.00 |
| Feb 20, 2026 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $86.00 |
| Feb 20, 2026 | RBC Capital | Brian Abrahams | Sector Perform | Maintains | $82.00 |
| Feb 20, 2026 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $93.00 |
| Jan 28, 2026 | Barclays | Eliana Merle | Overweight | Upgrade | $119.00 |
| Dec 1, 2025 | RBC Capital | Brian Abrahams | Sector Perform | Downgrade | $91.00 |
| Nov 6, 2025 | Barclays | Gena Wang | Equal-Weight | Maintains | $68.00 |
| Nov 5, 2025 | Goldman Sachs | Paul Choi | Sell | Maintains | $50.00 |
| Nov 5, 2025 | Wells Fargo | Benjamin Burnett | Overweight | Maintains | $93.00 |
| Nov 5, 2025 | RBC Capital | Brian Abrahams | Outperform | Maintains | $82.00 |
| Nov 5, 2025 | Citigroup | Geoff Meacham | Neutral | Maintains | $75.00 |
| Nov 5, 2025 | TD Cowen | Joseph Thome | Hold | Maintains | $63.00 |
| Oct 28, 2025 | Jefferies | Kelly Shi | Buy | Maintains | $77.00 |
| Sep 3, 2025 | Cantor Fitzgerald | Kristen Kluska | Overweight | Reiterates | $118.00 |
| Aug 20, 2025 | Morgan Stanley | Jeffrey Hung | Overweight | Maintains | $71.00 |
| Aug 20, 2025 | B of A Securities | Tazeen Ahmad | Buy | Maintains | $76.00 |
| Aug 20, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $73.00 |
| Aug 8, 2025 | Wells Fargo | Tiago Fauth | Overweight | Maintains | $79.00 |
| Aug 8, 2025 | Morgan Stanley | Overweight | Maintains | $N/A |
Ptc Therapeutics Inc. (PTCT) Competitors
The following stocks are similar to PTC Therapeutics based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
PTCT
PTC Therapeutics
mkt cap
5.40B
Ptc Therapeutics Inc. (PTCT) Financial Data
Ptc Therapeutics Inc. has a market capitalization of $6.11B with a P/E ratio of 7.5x. The company generates $1.73B in trailing twelve-month revenue with a 39.4% profit margin.
Revenue growth is -22.7% quarter-over-quarter, while maintaining an operating margin of -49.6% and return on equity of -332.5%.
Valuation Metrics
Market Cap
$6.11B
Enterprise Value
$6.27B
P/E Ratio
7.5x
PEG Ratio
0.1x
Price/Sales
3.1x
Growth & Margins
Revenue Growth (YoY)
-22.7%
Gross Margin
+95.8%
Operating Margin
-49.6%
Net Margin
+39.4%
EPS Growth
-22.7%
Financial Health
Cash/Price Ratio
+31.9%
Current Ratio
2.3x
Debt/Equity
-13.2x
ROE
-332.5%
ROA
+23.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Ptc Therapeutics Inc. (PTCT) Business Model
About Ptc Therapeutics Inc.
What They Do
Biopharmaceutical company developing treatments for rare disorders.
Business Model
The company focuses on the discovery, development, and commercialization of innovative medicines for rare disorders, particularly orphan diseases. It generates revenue through the sale of its approved drugs, collaborations on therapies, and potential future product launches in its pipeline.
Additional Information
PTC Therapeutics has a strong portfolio of approved products, including Translarna and Emflaza, and is actively working on investigational therapies for conditions such as phenylketonuria and Friedreich's ataxia. The company has established a patient-centric approach and has a global commercial infrastructure that supports its mission to address high unmet medical needs in the biopharmaceutical space.
Company Information
Sector
Healthcare
Industry
Biotechnology
Employees
939
CEO
Dr. Matthew B. Klein F.A.C.S., M.D., M.S.
Country
United States
IPO Year
2013
Website
www.ptcbio.comPtc Therapeutics Inc. (PTCT) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Compared to Estimates, PTC Therapeutics (PTCT) Q1 Earnings: A Look at Key Metrics
While the top- and bottom-line numbers for PTC Therapeutics (PTCT) give a sense of how the business performed in the quarter ended March 2026, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
May 07, 2026
By Zacks Equity Research
Fundamental Analysis
PTC Therapeutics (PTCT) Reports Q1 Loss, Tops Revenue Estimates
PTC Therapeutics (PTCT) delivered earnings and revenue surprises of +93.35% and +16.63%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?
May 07, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Exploring Analyst Estimates for PTC Therapeutics (PTCT) Q1 Earnings, Beyond Revenue and EPS
3 days ago
Quick Summary
PTC Therapeutics (PTCT) is focusing on key metrics beyond Wall Street's estimates to evaluate its performance for the quarter ending March 2026.
Why It Matters
Key metrics for PTC Therapeutics provide insights into potential growth and profitability, influencing investor sentiment and stock valuation ahead of earnings reports.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) executives will present at the Bank of America Securities Health Care Conference on May 12, 2026, at 8:40 a.m.
Why It Matters
PTC Therapeutics’ executives speaking at a major conference can indicate potential insights into company performance, strategy, and future developments, affecting investor sentiment and stock price.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
PTC Therapeutics Inc. (NASDAQ:PTCT) shares declined after the company released topline results from the 24-month interim analysis of its PIVOT-HD long-term extension study.
Why It Matters
The decline in PTC Therapeutics shares indicates negative investor sentiment following disappointing trial results, potentially impacting the company's future growth and valuation.
Source: Benzinga
Market Sentiment:
Negative
Quick Summary
PTC Therapeutics (PTCT) presented 24-month interim results from the PIVOT-HD study on Votoplam for Huntington's Disease, indicating progress in its long-term treatment evaluation.
Why It Matters
The interim results of PTC Therapeutics’ study on Votoplam could indicate the drug's efficacy and safety, influencing stock performance and investor confidence in the company's future growth.
Source: Seeking Alpha
Market Sentiment:
Neutral
PTC Therapeutics (PTCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q1 Release
9 days ago
Quick Summary
PTC Therapeutics (PTCT) is anticipated to potentially exceed earnings expectations in its upcoming report, according to key indicators.
Why It Matters
PTC Therapeutics' potential for an earnings beat suggests strong financial performance, which could drive stock price growth and attract investor interest.
Source: Zacks Investment Research
Market Sentiment:
Positive
Quick Summary
PTC Therapeutics, Inc. (NASDAQ: PTCT) will hold a webcast conference call today, April 28, 2026, at 4:30 p.m. for investors and stakeholders.
Why It Matters
The webcast conference call may provide key insights into PTC Therapeutics’ performance, strategies, or updates, potentially impacting stock valuation and investor sentiment.
Source: PRNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PTCT Stock
What is Ptc Therapeutics Inc.'s (PTCT) stock forecast for 2026?
Based on our analysis of 30 Wall Street analysts, Ptc Therapeutics Inc. (PTCT) has a median price target of $86.00. The highest price target is $124.00 and the lowest is $61.00.
Is PTCT stock a good investment in 2026?
According to current analyst ratings, PTCT has 9 Buy ratings, 5 Hold ratings, and 1 Sell ratings. The stock is currently trading at $73.69. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PTCT stock?
Wall Street analysts predict PTCT stock could reach $86.00 in the next 12 months. This represents a 16.7% increase from the current price of $73.69. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Ptc Therapeutics Inc.'s business model?
The company focuses on the discovery, development, and commercialization of innovative medicines for rare disorders, particularly orphan diseases. It generates revenue through the sale of its approved drugs, collaborations on therapies, and potential future product launches in its pipeline.
What is the highest forecasted price for PTCT Ptc Therapeutics Inc.?
The highest price target for PTCT is $124.00 from at , which represents a 68.3% increase from the current price of $73.69.
What is the lowest forecasted price for PTCT Ptc Therapeutics Inc.?
Price targets from Wall Street analysts for PTCT are not currently available. The stock is trading at $73.69.
What is the overall PTCT consensus from analysts for Ptc Therapeutics Inc.?
The overall analyst consensus for PTCT is bullish. Out of 30 Wall Street analysts, 9 rate it as Buy, 5 as Hold, and 1 as Sell, with a median price target of $86.00.
How accurate are PTCT stock price projections?
Stock price projections, including those for Ptc Therapeutics Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: May 9, 2026 12:37 PM UTC